Table 1 EC50 values for therapeutic PD-L1 and PD-1 antibodies estimated for their ability to block the PD-1/PD-L1 interaction in a functional assay and for their binding to their respective target antigens. Data from three independent experiments performed in duplicate were used to calculate EC50 values.

From: Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling

 

Functional EC50 values

Binding EC50 values

EC50 (ng/ml)

95% CI

EC50 (ng/ml)

95% CI

Atezolizumab

6.46

5.48–7.61

15.08

12.55–18.12

Avelumab

6.15

5.24–7.21

12.69

10.35–15.56

Durvalumab

7.64

6.52–8.96

13.76

12.03–15.75

Nivolumab

76.17

64.95–89.34

7.27

5.94–8.90

Pembrolizumab

39.90

34.01–46.80

7.89

6.52–9.56

Back to article page